{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:02:57Z","timestamp":1761948177926},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,11]]},"abstract":"Abstract<\/jats:title>The purpose of this study was to estimate the risk of developing skeletal\u2010related events (SRE<\/jats:styled-content>s) based on site of metastasis at diagnosis and identify other predictors of developing SRE<\/jats:styled-content>s among metastatic prostate cancer patients. We conducted a retrospective cohort study using linked SEER<\/jats:styled-content> (Surveillance, Epidemiology, and End Results) and Medicare data and identified men over the age of 65 with incident metastatic prostate cancer diagnosed during 2005\u20132009. SRE<\/jats:styled-content>s included radiation (RAD<\/jats:styled-content>), pathological fractures (PF<\/jats:styled-content>), bone surgery (BS<\/jats:styled-content>), and spinal cord compression (SCC<\/jats:styled-content>). The association between site of metastasis at diagnosis and SRE<\/jats:styled-content> was examined using a Cox proportional hazards model that accounts for death as a competing risk. Among 4404 men (median age: 79\u00a0years) with incident metastatic prostate cancer, 44% experienced SRE<\/jats:styled-content>s at a median of 9.6\u00a0months post diagnosis. Compared to bone metastasis only, our model showed that patients were significantly less likely to develop SRE<\/jats:styled-content>s if they had LN<\/jats:styled-content>\u2010only metastasis at diagnosis (Sub\u2010Hazard Ratio [SHR<\/jats:styled-content>] 0.56; 95% Confidence Interval [CI<\/jats:styled-content>]: 0.43\u20130.72) or unknown site of metastasis (SHR<\/jats:styled-content>: 0.79; CI<\/jats:styled-content>: 0.64\u20130.97). Other predictors of reduced SRE<\/jats:styled-content> risk were age 80+ years (SHR<\/jats:styled-content>: 0.83; CI<\/jats:styled-content>: 0.75\u20130.91), non\u2010Hispanic Black (SHR<\/jats:styled-content>: 0.77; CI<\/jats:styled-content>: 0.65\u20130.90), or being diagnosed in year 2009 (SHR<\/jats:styled-content>: 0.85; CI<\/jats:styled-content>: 0.72\u20130.99). Patients were significantly more likely to develop SRE<\/jats:styled-content>s if they received androgen deprivation therapy (SHR<\/jats:styled-content>: 1.73; CI<\/jats:styled-content>: 1.48\u20132.02) or had Gleason score 8\u201310 disease (SHR<\/jats:styled-content>: 0.79; CI<\/jats:styled-content>: 0.64\u20130.97). Compared to patients who present with bone metastasis only at diagnosis, patients presenting with other metastatic sites have similar risk of developing SRE<\/jats:styled-content>s, with the exception of those presenting with lymph node only metastasis who have a significantly reduced risk of SRE<\/jats:styled-content>s.<\/jats:p>","DOI":"10.1002\/cam4.914","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T17:24:36Z","timestamp":1476379476000},"page":"3300-3309","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis"],"prefix":"10.1002","volume":"5","author":[{"given":"Arif","family":"Hussain","sequence":"first","affiliation":[{"name":"University of Maryland School of Medicine Marlene and Stewart Greenebaum Cancer Center Baltimore Baltimore Maryland"},{"name":"Veterans Affairs Medical Center Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalla","family":"Aly","sequence":"additional","affiliation":[{"name":"Pharmerit International Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Daniel Mullins","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Arellano","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22742"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.020"},{"key":"e_1_2_7_4_1","volume-title":"The site of visceral metastases (mets) to predict overall survival (OS) in castration\u2010resistant prostate cancer (CRPC) patients (pts): a meta\u2010analysis of five phase III trials","author":"Halabi S."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.034"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2011.7"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.07.062"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9528"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000045"},{"key":"e_1_2_7_10_1","unstructured":"SEER\u2010Medicare: Brief description of the SEER\u2010Medicare database.2015."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29052"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0047-5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq439"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2258"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.09.013"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta17290"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi122"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12016"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.6500"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2010.49"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/88.2.545S"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S5446"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.914","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.914","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T21:25:14Z","timestamp":1694035514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/cam4.914"],"URL":"https:\/\/doi.org\/10.1002\/cam4.914","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]},"assertion":[{"value":"2015-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}